These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21743107)

  • 1. Progeria, rapamycin and normal aging: recent breakthrough.
    Blagosklonny MV
    Aging (Albany NY); 2011 Jul; 3(7):685-91. PubMed ID: 21743107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders.
    Graziotto JJ; Cao K; Collins FS; Krainc D
    Autophagy; 2012 Jan; 8(1):147-51. PubMed ID: 22170152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2014; 13(4):509-15. PubMed ID: 24496328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
    Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
    Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR signaling plays a critical role in the defects observed in muscle-derived stem/progenitor cells isolated from a murine model of accelerated aging.
    Takayama K; Kawakami Y; Lavasani M; Mu X; Cummins JH; Yurube T; Kuroda R; Kurosaka M; Fu FH; Robbins PD; Niedernhofer LJ; Huard J
    J Orthop Res; 2017 Jul; 35(7):1375-1382. PubMed ID: 27572850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.
    Evangelisti C; Cenni V; Lattanzi G
    Br J Clin Pharmacol; 2016 Nov; 82(5):1229-1244. PubMed ID: 26952863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longevity, aging and rapamycin.
    Ehninger D; Neff F; Xie K
    Cell Mol Life Sci; 2014 Nov; 71(22):4325-46. PubMed ID: 25015322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin as a target in hematological malignancies.
    Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
    Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J; Huang W
    PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.
    Totary-Jain H; Marks AR
    Cell Cycle; 2013 Mar; 12(6):861-2. PubMed ID: 23442794
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D.
    KrzeĊ›niak M; Zajkowicz A; Matuszczyk I; Rusin M
    Mech Ageing Dev; 2014 Jul; 139():11-21. PubMed ID: 24915467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From rapalogs to anti-aging formula.
    Blagosklonny MV
    Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin: one drug, many effects.
    Li J; Kim SG; Blenis J
    Cell Metab; 2014 Mar; 19(3):373-9. PubMed ID: 24508508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapalogs and mTOR inhibitors as anti-aging therapeutics.
    Lamming DW; Ye L; Sabatini DM; Baur JA
    J Clin Invest; 2013 Mar; 123(3):980-9. PubMed ID: 23454761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
    Lamming DW
    Cold Spring Harb Perspect Med; 2016 May; 6(5):. PubMed ID: 27048303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward rapamycin analog (rapalog)-based precision cancer therapy.
    Meng LH; Zheng XF
    Acta Pharmacol Sin; 2015 Oct; 36(10):1163-9. PubMed ID: 26299952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOR-inhibitors as gero-suppressors.
    Nikiforov M
    Aging (Albany NY); 2015 Dec; 7(12):1030-1. PubMed ID: 26796970
    [No Abstract]   [Full Text] [Related]  

  • 20. Gerosuppression by pan-mTOR inhibitors.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.